Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
09 Sep 2024
Historique:
accepted: 02 08 2024
received: 15 03 2023
revised: 10 04 2024
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 9 9 2024
Statut: aheadofprint

Résumé

Aneuploidy results in a stoichiometric imbalance of protein complexes that jeopardizes cellular fitness. Aneuploid cells thus need to compensate for the imbalanced DNA levels by regulating their RNA and protein levels, but the underlying molecular mechanisms remain unknown. Here, we dissected multiple diploid vs. aneuploid cell models. We found that aneuploid cells cope with transcriptional burden by increasing several RNA degradation pathways, and are consequently more sensitive to the perturbation of RNA degradation. At the protein level, aneuploid cells mitigate proteotoxic stress by reducing protein translation and increasing protein degradation, rendering them more sensitive to proteasome inhibition. These findings were recapitulated across hundreds of human cancer cell lines and primary tumors, and aneuploidy levels were significantly associated with the response of multiple myeloma patients to proteasome inhibitors. Aneuploid cells are therefore preferentially dependent on several key nodes along the gene expression process, creating clinically-actionable vulnerabilities in aneuploid cells.

Identifiants

pubmed: 39247952
pii: 747913
doi: 10.1158/2159-8290.CD-23-0309
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Marica Rosaria Ippolito (MR)

European Institute of Oncology, Milan, Italy.

Johanna Zerbib (J)

Tel Aviv University, Tel Aviv, Israel.

Yonatan Eliezer (Y)

Tel Aviv University, Tel Aviv, Israel.

Eli Reuveni (E)

Tel Aviv University, Israel.

Sonia Vigano (S)

European Institute of Oncology, Milano, Italy.

Giuseppina De Feudis (G)

European Institute of Oncology, Milan, Italy.

Eldad D Shulman (ED)

National Cancer Institute, Bethesda, United States.

Rachel Slutsky (R)

Tel Aviv University, Tel Aviv, Israel.

Tiangen Chang (T)

NCI, NIH, Bethesda, MD, United States.

Emma M Campagnolo (EM)

National Cancer Institute, Bethesda, United States.

Silvia Taglietti (S)

European Institute of Oncology, Milan, Italy.

Simone Scorzoni (S)

European Institute of Oncology, Savona, Italy, Italy.

Sara Gianotti (S)

European Institute of Oncology, Milan, Italy.

Sara Martin (S)

European Institute of Oncology, Milano, Italy.

Julia Muenzner (J)

Charité - Universitätsmedizin Berlin, Berlin, Berlin, Germany.

Michael Mulleder (M)

Charité - Universitätsmedizin Berlin, Berlin, Germany.

Nir Rozenblum (N)

Tel Aviv University, Tel Aviv, Israel.

Carmela Rubolino (C)

Istituto Italiano di Tecnologia, Italy.

Tal Ben-Yishay (T)

Tel Aviv University, Tel Aviv, Israel.

Kathrin Laue (K)

Tel Aviv University, Israel.

Ilaria Vigorito (I)

Centro Cardiologico Monzino, Milan, Milan, Italy.

Francesco Nicassio (F)

Istituto Italiano di Tecnologia (IIT), Milano, Italy.

Eytan Ruppin (E)

National Cancer Institute, Bethesda, MD, United States.

Markus Ralser (M)

Charité - Universitaetsmedizin Berlin, Berlin, Germany.

Francisca Vazquez (F)

Broad Institute, Cambridge, MA, United States.

Stefano Santaguida (S)

European Institute of Oncology IRCCS, Milan, Italy.

Uri Ben-David (U)

Tel Aviv University, Tel Aviv, Israel.

Classifications MeSH